Why the study?
Does subcutaneous tricyclo-DNA antisense oligonucleotide treatment improve SMN2 mRNA splicing and disease phenotype in mild type III SMA mice?
Population
Mild type III SMA mice
Design
Preclinical
Authors
Loading...
Suggests systemic antisense oligonucleotide delivery can cross the blood-brain barrier in animal models; leaves open whether.
Does subcutaneous tricyclo-DNA antisense oligonucleotide treatment improve SMN2 mRNA splicing and disease phenotype in mild type III SMA mice?
Systemic subcutaneous delivery of tcDNA AONs effectively crosses the blood-brain barrier and improves disease phenotype in a mouse model of mild type III SMA, offering a potential systemic therapeutic alternative.
Robin et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: